药明生物与再鼎医药就创新T细胞衔接子达成研究服务协议

人民财讯
Jan 14

  1月14日,药明生物宣布与再鼎医药已针对一款创新T细胞衔接子(TCE)签署研究服务协议,再鼎医药将获得该TCE在实体瘤适应症治疗上的全球独家开发与商业化权利。

  该TCE的发现是基于药明生物专有的CD3技术平台,并结合多特异性抗体研究能力和前沿生物学洞见。基于该平台开发的三款TCE分子目前均处于临床开发阶段。

  根据协议条款,药明生物将获得一笔首付款,并有资格获得开发、上市及销售里程碑付款,以及产品上市后的销售提成和再许可或其他BD交易付款。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10